An executive order aims to speed up how quickly psychedelic drugs for mental illness can move through the regulatory process.

President Trump has signed an executive order to make certain psychedelic drugs more available to treat mental health conditions, such as depression and anxiety. He directed $50 million in federal ...

A new executive order aims to speed up reviews of certain psychedelic drugs, as the Trump administration argues that new tools are needed to address the mental health crisis.

President Trump has signed an executive order to ease research restrictions on psychedelics, including the drug ibogaine, which is used in some countries to treat post-traumatic stress disorder.

Daniel Payne reports on how the health industry and Washington influence and impact each other. He joined STAT in 2025 after covering health care at POLITICO. You can reach Daniel on Signal at danielp ...

The order eases restrictions on psychedelic drugs like ibogaine to spur research on using them for medical purposes.

President Donald Trump was surprised to read on Saturday, during the announcement of an executive order fast-tracking psychedelics for treating mental health conditions (full video here), that some ...

Psychedelic drugs, once pushed to the fringes of medicine, are gaining serious attention within the Trump administration as potential treatment options for people with certain mental health conditions ...